303
Participants
Start Date
November 28, 2023
Primary Completion Date
May 10, 2028
Study Completion Date
May 10, 2028
Dupilumab
Dupilumab cohort
Investigational Site Number: 2500020, Nice
Investigational Site Number: 2500029, Marseille
Investigational Site Number: 2500043, Caen
Investigational Site Number: 2500005, Dijon
Investigational Site Number: 2500009, Périgueux
Investigational Site Number: 2500001, Besançon
Investigational Site Number: 2500010, Valence
Investigational Site Number: 2500014, Romans-sur-Isère
Investigational Site Number: 2500012, Toulouse
Investigational Site Number: 2500028, Montpellier
Investigational Site Number: 2500045, La Tronche
Investigational Site Number: 2500024, Nantes
Investigational Site Number: 2500026, Saint-Nazaire
Investigational Site Number: 2500037, Angers
Investigational Site Number: 2500031, Vandœuvre-lès-Nancy
Investigational Site Number: 2500036, Lorient
Investigational Site Number: 2500011, Ars-Laquenexy
Investigational Site Number: 2500032, Lille
Investigational Site Number: 2500044, Armentières
Investigational Site Number: 2500018, Arras
Investigational Site Number: 2500006, Clermont-Ferrand
Investigational Site Number: 2500016, Pau
Investigational Site Number: 2500003, Bron
Investigational Site Number: 2500040, Le Mans
Investigational Site Number: 2500050, Chambéry
Investigational Site Number: 2500004, Epagny Metz Tessy
Investigational Site Number: 2500008, Rouen
Investigational Site Number: 2500019, Le Havre
Investigational Site Number: 2500015, Saint-Germain-en-Laye
Investigational Site Number: 2500041, Amiens
Investigational Site Number: 2500023, Avignon
Investigational Site Number: 2500038, Les Sables-d'Olonne
Investigational Site Number: 2500042, Poitiers
Investigational Site Number: 2500002, Limoges
Investigational Site Number: 2500048, Levallois-Perret
Investigational Site Number: 2500027, Saint-Mandé
Investigational Site Number: 2500021, Argenteuil
Investigational Site Number: 2500022, Pontoise
Investigational Site Number: 2500039, Fort-de-France
Investigational Site Number: 2500035, Saint-Pierre
Investigational Site Number: 2500013, Saint-Pierre
Investigational Site Number: 2500025, Nice
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY